Search

Your search keyword '"Landmesser, U."' showing total 1,110 results
Start Over Author "Landmesser, U."
1,110 results on '"Landmesser, U."'

2. High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany

Author

Makhmudova, U., Schatz, U., Perakakis, N., Kassner, U., Schumann, F., Axthelm, C., Stürzebecher, P., Sinning, D. L., Doevelaar, A., Rohn, B., Westhoff, T., Vogt, A., Scholl, M., Kästner, U., Geiling, J.-A., Stach, K., Mensch, J., Lorenz, E., Paitazoglou, C., Eitel, I., Baessler, A., Steinhagen-Thiessen, E., Koenig, W., Schulze, P. C., Landmesser, U., Laufs, U., and Weingärtner, Oliver

Published
2023
Full Text
View/download PDF

4. TAVI PACER - a contemporary risk score for pacemaker implantation after TAVI

Author

Lueg, J, primary, Janiszewski, A, additional, Schulze, D, additional, Juri, B, additional, Morell, L, additional, Hajduczenia, M, additional, Hennig, P, additional, Erbay, A, additional, Niehues, S, additional, Landmesser, U, additional, Stangl, K, additional, Leistner, D M, additional, Dreger, H, additional, and Tscholl, V, additional

Published
2024
Full Text
View/download PDF

9. Foxo3a and cardiac myofibroblast transdifferentiation after myocardial infarction

Author

Karadeniz, Z, primary, Schenkenberger, P, additional, Maatz, H, additional, Lindberg, E, additional, Haase, T, additional, Thiele, A, additional, Thevathasan, T, additional, Kraenkel, N, additional, Taupitz, M, additional, Kintscher, U, additional, Kurreck, J, additional, Scheibenbogen, C, additional, Landmesser, U, additional, Huebner, N, additional, and Skurk, C, additional

Published
2023
Full Text
View/download PDF

10. Safety and healthcare resource utilisation in patients undergoing left-atrial appendage closure - A nationwide analysis

Author

Thevathasan, T, primary, Degbeon, S, additional, Paul, J, additional, Fuereder, L, additional, Gaul, A L, additional, Scheitz, J F, additional, Stadler, G, additional, Rroku, A, additional, Lech, S, additional, Buspavanich, P, additional, Huemer, M, additional, Reinthaler, M, additional, Landmesser, U, additional, and Skurk, C, additional

Published
2023
Full Text
View/download PDF

11. Left-ventricular unloading with Impella during refractory cardiac arrest treated with veno-arterial extracorporeal membrane oxygenation - A systematic review and meta-analysis

Author

Thevathasan, T, primary, Fuereder, L, additional, Mork, S R, additional, Schrage, B, additional, Gaisendrees, C, additional, Unoki, T, additional, Axtell, A L, additional, Takeda, K, additional, Teixeira, P G, additional, Lemaire, A, additional, Alonso-Fernandez-Gatta, M, additional, Lim, H S, additional, Garan, A R, additional, Landmesser, U, additional, and Skurk, C, additional

Published
2023
Full Text
View/download PDF

15. Patient-reported functional and symptomatic outcomes in patients with mild cognitive disorder undergoing transcatheter aortic valve implantation - A secondary analysis of a randomized controlled trial

Author

Thevathasan, T, primary, Hornig, C, additional, Leistner, D M, additional, Suendermann, S, additional, Unbehaun, A, additional, Sherif, M, additional, Haghikia, A, additional, Stangl, K, additional, Falk, V, additional, Landmesser, U, additional, Dreger, H, additional, Stangl, V, additional, and Brand, A, additional

Published
2023
Full Text
View/download PDF

22. Gene diagnostics for cardiovascular diseases

Author

Schulze-Bahr, E., primary, Klaassen, S., additional, Gerull, B., additional, von Kodolitsch, Y., additional, Landmesser, U., additional, Rieß, O., additional, Meder, B., additional, and Schunkert, H., additional

Published
2023
Full Text
View/download PDF

28. Macrophage uptake switches on OCT contrast of superparamagnetic nanoparticles for imaging of atherosclerotic plaques

Author

Ariza de Schellenberger A, Poller WC, Stangl V, Landmesser U, and Schellenberger E

Subjects
Atherosclerotic plaques, macrophages, ferumoxytol, superparamagnetic iron oxide particles, Optical coherence tomography, Magnetic resonance imaging, Medicine (General), R5-920
Abstract

Angela Ariza de Schellenberger,1,* Wolfram C Poller,2,* Verena Stangl,2 Ulf Landmesser,3 Eyk Schellenberger1 1Department of Radiology, Charité-Universitätsmedizin Berlin, Germany; 2Department of Interventional Cardiology, Charité-Universitätsmedizin Berlin, Germany; 3Department of Cardiology, Charité- Universitätsmedizin Berlin, Berlin Institute of Health (BIH) and Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), Berlin, Germany *These authors contributed equally to this work Background: Optical coherence tomography (OCT) is an intravascular, high-resolution imaging technique that is used to characterize atherosclerotic plaques. However, the identification of macrophages as important markers of inflammation and plaque vulnerability remains difficult. Here, we investigate whether the uptake of very small iron oxide particles (VSOP) in macrophages, that cluster in phagolysosomes and allow high-quality magnetic resonance imaging (MRI) of atherosclerotic plaques, and uptake of ferumoxytol nanoparticles enhance detection of macrophages by OCT.Materials and methods: RAW 264.7 macrophage cells were incubated with VSOP (1 and 2 mM Fe) that have been clinically tested and ferumoxytol (8.9 mM Fe) that is approved for iron deficiency treatment and currently investigated as an MRI contrast agent. The light scattering of control macrophages, nanoparticle-labeled macrophages (2,000,000 in 500 µL) and nanoparticle suspensions was measured in synchronous wavelength scan mode using a fluorescence spectrophotometer. For OCT analyses, pellets of 8,000,000 non-labeled, VSOP-labeled and ferumoxytol-labeled RAW 264.7 macrophages were imaged and analyzed on an OPTIS™ OCT imaging system.Results: Incubation with 1 and 2 mM VSOP resulted in uptake of 7.1±1.5 and 12±1.5 pg Fe per cell, which increased the backscattering of the macrophages in spectrophotometry 2.5- and 3.6-fold, whereas incubation with 8.9 mM Fe ferumoxytol resulted in uptake of 6.6±2 pg Fe per cell, which increased the backscattering 1.5-fold at 700 nm. In contrast, backscattering of non-clustered nanoparticles in suspension was negligible. Accordingly, OCT imaging could visualize significantly increased backscattering and signal attenuation of nanoparticle-labeled macrophages in comparison with controls.Conclusion: We conclude that VSOP and, to a lesser extent, ferumoxytol increase light scattering and attenuation when taken up by macrophages and can serve as a multimodal imaging probe for MRI and OCT to improve macrophage detection in atherosclerotic plaques by OCT in the future. Keywords: intravascular, inflammation, vulnerability, multimodal imaging, optical coherence tomography, magnetic resonance imaging

Published
2018

29. Clinical quantitative coronary artery stenosis and coronary atherosclerosis imaging: a Consensus Statement from the Quantitative Cardiovascular Imaging Study Group

Author

Mézquita, AJV, Biavati, F, Falk, V, Alkadhi, H, Hajhosseiny, R, Maurovich-Horvat, P, Manka, R, Kozerke, S, Stuber, M, Derlin, T, Channon, KM, Išgum, I, Coenen, A, Foellmer, B, Dey, D, Volleberg, RHJA, Meinel, FG, Dweck, MR, Piek, JJ, van de Hoef, T, Landmesser, U, Guagliumi, G, Giannopoulos, AA, Botnar, RM, Khamis, R, Williams, MC, Newby, DE, Dewey, M, and University of Zurich

Subjects
10042 Clinic for Diagnostic and Interventional Radiology, 610 Medicine & health, 10181 Clinic for Nuclear Medicine
Abstract

The detection and characterization of coronary artery stenosis and atherosclerosis using imaging tools are key for clinical decision-making in patients with known or suspected coronary artery disease. In this regard, imaging-based quantification can be improved by choosing the most appropriate imaging modality for diagnosis, treatment and procedural planning. In this Consensus Statement, we provide clinical consensus recommendations on the optimal use of different imaging techniques in various patient populations and describe the advances in imaging technology. Clinical consensus recommendations on the appropriateness of each imaging technique for direct coronary artery visualization were derived through a three-step, real-time Delphi process that took place before, during and after the Second International Quantitative Cardiovascular Imaging Meeting in September 2022. According to the Delphi survey answers, CT is the method of choice to rule out obstructive stenosis in patients with an intermediate pre-test probability of coronary artery disease and enables quantitative assessment of coronary plaque with respect to dimensions, composition, location and related risk of future cardiovascular events, whereas MRI facilitates the visualization of coronary plaque and can be used in experienced centres as a radiation-free, second-line option for non-invasive coronary angiography. PET has the greatest potential for quantifying inflammation in coronary plaque but SPECT currently has a limited role in clinical coronary artery stenosis and atherosclerosis imaging. Invasive coronary angiography is the reference standard for stenosis assessment but cannot characterize coronary plaques. Finally, intravascular ultrasonography and optical coherence tomography are the most important invasive imaging modalities for the identification of plaques at high risk of rupture. The recommendations made in this Consensus Statement will help clinicians to choose the most appropriate imaging modality on the basis of the specific clinical scenario, individual patient characteristics and the availability of each imaging modality.

Published
2023

32. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)

Author

Lyon, A. R., Lopez-Fernandez, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., Cutter, D. J., de Azambuja, E., de Boer, R. A., Dent, S. F., Farmakis, D., Gevaert, S. A., Gorog, D. A., Herrmann, J., Lenihan, D., Moslehi, J., Moura, B., Salinger, S. S., Stephens, R., Suter, T. M., Szmit, S., Tamargo, J., Thavendiranathan, P., Tocchetti, C. G., van der Meer, P., van der Pal, H. J. H., Lancellotti, P., Thuny, F., Abdelhamid, M., Aboyans, V., Aleman, B., Alexandre, J., Barac, A., Borger, M. A., Casado-Arroyo, R., Cautela, J., Celutkiene, J., Cikes, M., Cohen-Solal, A., Dhiman, K., Ederhy, S., Edvardsen, T., Fauchier, L., Fradley, M., Grapsa, J., Halvorsen, S., Heuser, M., Humbert, M., Jaarsma, T., Kahan, T., Konradi, A., Koskinas, K. C., Kotecha, D., Ky, B., Landmesser, U., Lewis, B. S., Linhart, A., Lip, G. Y. H., Lochen, M. -L., Malaczynska-Rajpold, K., Metra, M., Mindham, R., Moonen, M., Neilan, T. G., Nielsen, J. C., Petronio, A. -S., Prescott, E., Rakisheva, A., Salem, J. -E., Savarese, G., Sitges, M., Ten Berg, J., Touyz, R. M., Tycinska, A., Wilhelm, M., Zamorano, J. L., Cardiovascular Centre (CVC), Restoring Organ Function by Means of Regenerative Medicine (REGENERATE), Group, ESC Scientific Document, Lyon, Alexander R, López-Fernández, Teresa, Couch, Liam S, Asteggiano, Riccardo, Aznar, Marianne C, Bergler-Klein, Jutta, Boriani, Giuseppe, Cardinale, Daniela, Cordoba, Raul, Cosyns, Bernard, Cutter, David J, de Azambuja, Evandro, de Boer, Rudolf A, Dent, Susan F, Farmakis, Dimitrio, Gevaert, Sofie A, Gorog, Diana A, Herrmann, Joerg, Lenihan, Daniel, Moslehi, Javid, Moura, Brenda, Salinger, Sonja S, Stephens, Richard, Suter, Thomas M, Szmit, Sebastian, Tamargo, Juan, Thavendiranathan, Paaladinesh, Tocchetti, Carlo G, van der Meer, Peter, van der Pal, Helena J H, Cardiology, Clinical sciences, and Cardio-vascular diseases

Subjects
Cardiac magnetic resonance, Cancer survivors, Vascular endothelial growth factor inhibitors (VEGFi), Myocarditi, Guideline, Anthracycline, Arrhythmias, Medical Oncology, T-CELL THERAPY, Coronary artery disease, Strain, RECURRENT VENOUS THROMBOEMBOLISM, Amyloid light-chain cardiac amyloidosis, Androgen deprivation therapy, Atrial fibrillation, Biomarkers, Cancer, Carcinoid syndrome, Cardiac tumour, Cardio-oncology, Cardiotoxicity, Chemotherapy, Echocardiography, Fluoropyrimidine, Guidelines, Haematopoietic stem cell transplantation, Heart failure, Hormone therapy, Hypertension, Immunotherapy, Ischaemic heart disease, Myocarditis, Pericardial disease, Proteasome inhibitors, Pulmonary hypertension, QTc prolongation, Radiotherapy, Risk stratification, Thrombosis, Trastuzumab, Valvular heart disease, Venous thromboembolism, Neoplasms, Proteasome inhibitor, Amyloid light-chain cardiac amyloidosi, IMMUNE CHECKPOINT INHIBITORS, Cardiotoxicity/diagnostic imaging, Heart, General Medicine, Hematology, MOLECULAR-WEIGHT HEPARIN, BRAIN NATRIURETIC PEPTIDE, oncology, Cancer survivor, Thrombosi, CORONARY-ARTERY-DISEASE, Cardiology and Cardiovascular Medicine, TYROSINE KINASE INHIBITOR, Arrhythmia, Neoplasms/diagnostic imaging, Antineoplastic Agents, Humans, Radiology, Nuclear Medicine and imaging, EARLY BREAST-CANCER, CARCINOID HEART-DISEASE, Antineoplastic Agents/therapeutic use, Biomarker, AORTIC-VALVE-REPLACEMENT, Radiation Oncology
Published
2022

34. Kommentar zu den 2015‑Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zum Management des akuten Koronarsyndroms ohne ST‑Hebungen (NSTE-ACS)

Author

Mehilli, J., Hamm, C., Landmesser, U., and Massberg, S.

Abstract

Die neue NSTE-ACS (akutes Koronarsyndrom ohne ST-Hebungen)-Leitlinie der Europäischen Gesellschaft für Kardiologie (ESC) inkorporiert wichtige aktuelle Erkenntnisse insbesondere hinsichtlich der Früherkennung des NSTE-ACS und erleichtert über einen 0‑h/1-h-Algorithmus die Triage in den „chest pain units“. Bezüglich der Dauer der antithrombotischen Therapie nach perkutaner Koronarintervention bei NSTE-ACS bleiben 12 Monate der Standard, kürzere wie auch längere Therapiephasen sind jedoch entsprechend aktueller Studienergebnisse nach individueller Risiko-Nutzen-Abwägung in Ausnahmefällen möglich. Bei ACS-Patienten mit zusätzlicher Indikation zur oralen Antikoagulation wird weiterhin eine Triple-Therapie empfohlen, deren Dauer sich nach dem individuellen Blutungs- und Ischämierisiko richten muss. Bei Patienten mit nichtvalvulärem Vorhofflimmern sind aufgrund ihres günstigeren Risikoprofils hinsichtlich Blutung nun auch neue orale Antikoagulanzien (NOAKs) als Alternative zu Vitamin-K-Antagonisten (VKA) in den Leitlinien verankert. Randomisierte Studien prüfen derzeit den Stellenwert von NOAKs, aber auch dualer Behandlungskonzepte (orale Antikoagulation plus antithrombozytäre Monotherapie) in der akuten und chronischen Phase. The new European Society of Cardiology (ESC) guidelines on non-ST elevation acute coronary syndrome (NSTE-ACS) reflect important current scientific evidence regarding early diagnosis of NSTE-ACS and facilitate better patient triage in chest pain units using a 0 h/1 h rule in/rule out algorithm. Furthermore, 12 months remain the standard duration of antithrombotic therapy after percutaneous coronary intervention (PCI) for NSTE-ACS, while based on current evidence shorter or longer treatment duration is possible in exceptional cases after careful consideration of the individual patient risks and benefits. For ACS patients with additional indications for oral anticoagulation, triple therapy is still recommended and the duration strongly depends on individual risks of bleeding and ischemia. In addition, due to a favorable safety profile, non-vitamin K oral anticoagulants (NOAC) might be considered in patients with non-valvular atrial fibrillation as an alternative to vitamin K antagonists (VKA). There are several randomized trials currently investigating both NOAC and different dual antithrombotic treatment strategies (e.g. OAC plus antiplatelet monotherapy) in the acute and chronic phases of ACS.

Published
2024
Full Text
View/download PDF

38. Hand grip strength in patients with advanced cancer : A prospective study

Author

Hadzibegovic, S., Porthun, J., Lena, A., Weinlaänder, P., Lück, L.C., Potthoff, S.K., Rösnick, L., Fröhlich, A.K., Ramer, L.V., Sonntag, F., Wilkenshoff, U., Ahn, J., Keller, U., Bullinger, L., Mahabadi, A.A., Totzeck, M., Rassaf, T., von Haehling, S., Coats, A.J.S., Anker, S.D., Roeland, E.J., Landmesser, U., and Anker, M.S.

Subjects
Cancer Research, Medizin
Abstract

Background: Hand grip strength (HGS) is a widely used functional test for the assessment of strength and functional status in patients with cancer, in particular with cancer cachexia. The aim was to prospectively evaluate the prognostic value of HGS in patients with mostly advanced cancer with and without cachexia and to establish reference values for a European-based population. Methods: In this prospective study, 333 patients with cancer (85% stage III/IV) and 65 healthy controls of similar age and sex were enrolled. None of the study participants had significant cardiovascular disease or active infection at baseline. Repetitive HGS assessment was performed using a hand dynamometer to measure the maximal HGS (kilograms). Presence of cancer cachexia was defined when patients had ≥5% weight loss within 6 months or when body mass index was

Published
2023

48. High individual variability in LDL-reductions after inclisiran administration in a “real-world setting”

Author

Makhmudova, U, primary, Schatz, U, additional, Kassner, U, additional, Axthelm, C, additional, Rohn, B, additional, Westhoff, T, additional, Vogt, A, additional, Scholl, M, additional, Stach, K, additional, Sinnig, D L, additional, Stuerzebecher, P, additional, Schulze, P C, additional, Landmesser, U, additional, Laufs, U, additional, and Weingaertner, O, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results